The holiday shopping marathon that began at the start of November and will end in less than a week has become a sprint. As retailers face having only days to improve their sales results, they have turned to a part of their playbook that did not even exist a few years ago — free shipping. The tactic is particularly critical to e-commerce business. Put simply — people cannot buy what they cannot get their hands on.
Like most retailers with an online presence, Wal-Mart Stores Inc. (NYSE: WMT) has several levels of free shipping and has decided to pressure customers with the message that the chances to use the service are about to come to an end. Orders from Walmart.com�of $35 or more can still ship free�via standard delivery, which takes as much as five days. Tardy shoppers have to pay a premium to get “rush shipping” until December 22. The price for the privilege is high enough that Walmart does not post it. As the retailer says, “prices vary per item.”
Top 10 Railroad Companies To Invest In Right Now: Carnival Plc ADS (CUK)
Carnival plc operates as a cruise company. It operates in North America Cruise Brands, EAA Cruise Brands, and Tour and Other segments. The company offers cruises under the brand names of Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn in North America; and AIDA Cruises, Costa Cruises, Cunard, Ibero Cruises, P&O Cruises (UK), and P&O Cruises (Australia) in Europe, Australia, and Asia. It also owns Holland America Princess Alaska Tours, a tour operator in Alaska and the Canadian Yukon, which owns and operates 12 hotels or lodges, 300 motor coaches, and 20 domed rail cars. The company sells its cruises through travel agents, including wholesalers, general sales agents, and tour operators. Carnival plc was founded in 1850 and is headquartered in London, the United Kingdom.
Advisors' Opinion:- [By Myra Ramdenbourg]
Carnival PLC (CUK): CFO David Bernstein Sold 11,673 Shares
On 01/21/2014, CFO David Bernstein sold 11,673 shares at an average price of $40.80. The price of the stock has decreased by 1.2% since. Carnival PLC has a market cap of $32.57 billion and its shares were traded at around $40.31. The company has a P/E ratio of 29.10 and P/S ratio of 2.03; the dividend yield is 2.48%. Over the past 10 years, Carnival PLC had an annual average earnings growth of 0.30%.
Hot Shipping Stocks To Own Right Now: Bovis Homes Group PLC (BVS)
Bovis Homes Group PLC is a builder of traditional homes in England and Wales. The Company�� business involves the designing, building and selling of new homes for both private and public sector customers. The Company delivers projects such as Land acquisition, Planning, Legal, Design, Surveying, Engineering, Purchasing, Construction, Sales and marketing, Public relations and Customer service. Advisors' Opinion:- [By Inyoung Hwang]
Bovis Homes Group Plc (BVS) climbed 4 percent to 790 pence. Liberum Capital Ltd. raised its rating on the housebuilder to buy from hold. Persimmon Plc (PSN), the U.K.�� largest residential property developer, gained 2.5 percent to 1,255 pence.
Hot Shipping Stocks To Own Right Now: Flushing Financial Corporation (FFIC)
Flushing Financial Corporation operates as the holding company of Flushing Savings Bank, FSB that provides banking products and services primarily to consumers and businesses. The company?s deposit products include savings accounts, money market accounts, demand accounts, negotiable order of withdrawal accounts, and certificates of deposit. Its loan products portfolio comprises one-to-four family, multi-family residential, and commercial real estate mortgage loans; construction loans, primarily for residential properties; small business administration loans and other small business loans; mortgage loan surrogates, such as mortgage-backed securities; U.S. government securities, corporate fixed-income securities, and other marketable securities; and consumer loans, including overdraft lines of credit. The company also offers Internet banking services through iGObanking.com. As of December 31, 2010, it conducted its business through 16 full-service offices located in the New York City Boroughs of Queens, Brooklyn, and Manhattan, as well as in Nassau County, New York. The company was founded in 1929 and is based in Lake Success, New York.
Advisors' Opinion:- [By Marc Bastow]
Savings and loan holding company Flushing Financial (FFIC) raised its quarterly dividend 15% to 15 cents per share, payable March 28 to shareholders of record as of March 7.
FFIC Dividend Yield: 2.86% - [By Tim Melvin]
I always find it very interesting to see what long-term investors are selling in a given quarter. Kahn Brothers lightened up on many financials that have shot up and now trade above book value. The firm sold out of Flushing Financial (FFIC), TCF Financial (TCB) and Dime Community Bank (DCOM). Khan apparently shares my views on the large-cap drug stocks, easing up on both Pfizer (PFE) and Bristol Meyers (BMY) over the summer. Khan Brothers also sold the last of the Travelers shares (TRV) it has owned since 2008 at more than twice the purchase price.
Hot Shipping Stocks To Own Right Now: Elan Corporation PLC (ELN)
Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.
Tysabri
Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.
In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.
Beta Amyloid Immunotherapies (AIP)
Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).
ELND005, an A� Aggregation Inhibitor
The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.
Neotope Biosciences Limited
Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.
Onclave Therapeutics Limited
Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.
The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.
Advisors' Opinion:- [By Tim Brugger]
Following the denial of an acquisition offer from Royalty Pharma on April 22 equal to $11.25 a share, or less, for all of Elan's (NYSE: ELN ) outstanding shares, a revised offer from Royalty of $12.50 a share has also been rejected, Elan announced today.
Hot Shipping Stocks To Own Right Now: QCR Holdings Inc.(QCRH)
QCR Holdings, Inc., through its subsidiaries, provides commercial and consumer banking, and trust and asset management services for the Quad City, Cedar Rapids, and Rockford communities. The company accepts deposits and invests in loans/leases and securities. Its deposit products comprise interest bearing deposits, non-interest bearing and interest bearing demand deposits, savings deposits, time deposits, and brokered time deposits. The company also offers a range of commercial and retail lending and investment services to corporations, partnerships, individuals, and government agencies. Its loan portfolio comprises commercial loans, including loans to wholesalers, manufacturers, building contractors, business services companies, other banks, and retailers; business loans, which include lines of credit for working capital and operational purposes; term loans for the acquisition of facilities, equipment, and other purposes; commercial real estate loans; and consumer loans c omprising motor vehicle, home improvement, home equity, and signature loans, as well as small personal credit lines. In addition, the company engages in the direct financing lease contracts; holding the real estate property; and issuing various trust preferred securities. QCR Holdings was founded in 1993 and is headquartered in Moline, Illinois.
Advisors' Opinion:- [By Tim Melvin]
QCR Holdings (QCRH) is another bank that has consistently had a lower return on assets than its peer group. The Illinois based bank has 9 offices and about $2.4 billion in total assets. The bank has an equity-to-assets ratio of just 7.4, which is well below the national average. The Illinois market has seen strong merger and acquisition activity in the past year, and this bank could become a target .
Hot Shipping Stocks To Own Right Now: First Trust Portfolios LP (QQEW)
First Trust NASDAQ-100 Equal Weighted Index Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the NASDAQ-100 Equal Weighted Index (the Index). The Fund will normally invest at least 90% of its assets in common stocks that comprise the Index. The Index is the equal-weighted version of the NASDAQ-100 Index, which includes 100 of the largest non-financial securities listed on NASDAQ based on market capitalization. The Index contains the same securities as the NASDAQ-100 Index but each of the securities is initially set at a weight of 1% of the Index and is rebalanced quarterly. The Fund�� investment advisor is First Trust Advisors L.P. Advisors' Opinion:- [By Selena Maranjian]
Perhaps the best reason to pass up this otherwise solid ETF is its market-cap-based weighting, which gives much more influence to some companies than others. If you're not a strong believer in Apple's future, for example, you may not want more than 13% of your money in this ETF tied up in it. If you agree that equal weighting makes more sense in indexes, consider the First Trust NASDAQ-100 Equal Weighted ETF (NASDAQ: QQEW ) , an ETF with the same stock focus as the PowerShares ETF that's also compelling in terms of fees and performance. It charges a bit more in fees, but it will give all its holdings an equal shot at boosting the value of the index.
No comments:
Post a Comment